Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Pomalidomide, Dexamethasone and ASCT in Relapsed/Refractory Multiple Myeloma
NCT03202628Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 18 Months. Started Jul 2017; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03202628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202628.